TITLE:
Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)

CONDITION:
Pulmonary Arterial Hypertension

INTERVENTION:
Iloprost or placebo

SUMMARY:

      The purpose of this study is to determine the safety and efficacy of Iloprost in subjects
      that have Pulmonary Arterial Hypertension who are concurrently taking bosentan (Tracleer
      TM).
    

DETAILED DESCRIPTION:

      This is a randomized, placebo-controlled study in subjects with Pulmonary Arterial
      Hypertension (PAH) with an NYHA Class of III or IV who are receiving conventional therapy
      and bosentan. Subjects who fulfill the inclusion and exclusion criteria will be randomized
      to study drug (active or placebo) at a frequency of 6-9 inhalations per day for 12 weeks and
      will continue conventional therapy and bosentan. At the end of the double-blind phase study,
      open label Iloprost will be provided.
    

ELIGIBILITY:
Gender: All
Age: 12 Years to 75 Years
Criteria:

        Inclusion Criteria:

          -  Diagnosis of PAH due to PPH, connective tissue disease, HIV, or repaired ( 1 year)
             ASD, VSD, or PDA

          -  NYHA Functional Class III or IV

          -  On bosentan for at least 16 weeks, with the dose stable (maximum dose 125 mg BID) for
             at least 8 weeks

          -  Age 12-75 years, of either gender

          -  Six minute walk distance 100-425 meters at Baseline

        Exclusion Criteria:

          -  Any new long-term treatment for PAH added within the last 4 weeks

          -  Any therapy with a PDE (phosphodiesterase), L -arginine or a prostaglandin,
             concurrently, or within the last 4 weeks

          -  PAH related to chronic thromboembolic disease, portopulmonary disease, or any
             etiology other than PPH, connective tissue disease, HIV, or repaired ASD, VSD, or PDA
      
